Sara Lundsten Salomonsson

p53 stabilisation potentiates [¹⁷⁷Lu]Lu-DOTATATE treatment in neuroblastoma xenografts

Berglund, Hanna; Lundsten Salomonsson, Sara; Mohajershojai, Tabassom; Ferrer Gago, Fernando Jose et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 768-778, 2024

• DOI för p53 stabilisation potentiates [¹⁷⁷Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
• Ladda ner fulltext (pdf) av p53 stabilisation potentiates [¹⁷⁷Lu]Lu-DOTATATE treatment in neuroblastoma xenografts

Modelling ligand depletion for simultaneous affinity and binding site quantification on cells and tissue

Weber, Judith; Djurberg, Klara; Lundsten, Sara; Kamprath, Maria et al.

Ingår i Scientific Reports, 2023

• DOI för Modelling ligand depletion for simultaneous affinity and binding site quantification on cells and tissue
• Ladda ner fulltext (pdf) av Modelling ligand depletion for simultaneous affinity and binding site quantification on cells and tissue

Photoactive immunoconjugates for targeted photodynamic therapy of cancer

Fernandes, Sara R.G.; Mohajershojai, Tabassom; Lundsten, Sara; Sarmento, Bruno et al.

Ingår i Journal of Photochemistry and Photobiology. B, 2023

• DOI för Photoactive immunoconjugates for targeted photodynamic therapy of cancer

Searching for Synergy: Radiosensitization of ¹⁷⁷Lu-DOTATATE

Lundsten, Sara

2022

• Ladda ner fulltext (pdf) av Searching for Synergy: Radiosensitization of ¹⁷⁷Lu-DOTATATE

p53-Mediated Radiosensitization of ¹⁷⁷Lu-DOTATATE in Neuroblastoma Tumor Spheroids

Lundsten, Sara; Berglund, Hanna; Jha, Preeti; Krona, Cecilia et al.

Ingår i Biomolecules, 2021

• DOI för p53-Mediated Radiosensitization of ¹⁷⁷Lu-DOTATATE in Neuroblastoma Tumor Spheroids
• Ladda ner fulltext (pdf) av p53-Mediated Radiosensitization of ¹⁷⁷Lu-DOTATATE in Neuroblastoma Tumor Spheroids

p53 stabilisation potentiates [¹⁷⁷Lu]Lu-DOTATATE treatment in neuroblastoma xenografts

Berglund, Hanna; Lundsten Salomonsson, Sara; Mohajershojai, Tabassom; Ferrer Gago, Fernando Jose et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 768-778, 2024

• DOI för p53 stabilisation potentiates [¹⁷⁷Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
• Ladda ner fulltext (pdf) av p53 stabilisation potentiates [¹⁷⁷Lu]Lu-DOTATATE treatment in neuroblastoma xenografts

Modelling ligand depletion for simultaneous affinity and binding site quantification on cells and tissue

Weber, Judith; Djurberg, Klara; Lundsten, Sara; Kamprath, Maria et al.

Ingår i Scientific Reports, 2023

• DOI för Modelling ligand depletion for simultaneous affinity and binding site quantification on cells and tissue
• Ladda ner fulltext (pdf) av Modelling ligand depletion for simultaneous affinity and binding site quantification on cells and tissue

Photoactive immunoconjugates for targeted photodynamic therapy of cancer

Fernandes, Sara R.G.; Mohajershojai, Tabassom; Lundsten, Sara; Sarmento, Bruno et al.

Ingår i Journal of Photochemistry and Photobiology. B, 2023

• DOI för Photoactive immunoconjugates for targeted photodynamic therapy of cancer

p53-Mediated Radiosensitization of ¹⁷⁷Lu-DOTATATE in Neuroblastoma Tumor Spheroids

Lundsten, Sara; Berglund, Hanna; Jha, Preeti; Krona, Cecilia et al.

Ingår i Biomolecules, 2021

• DOI för p53-Mediated Radiosensitization of ¹⁷⁷Lu-DOTATATE in Neuroblastoma Tumor Spheroids
• Ladda ner fulltext (pdf) av p53-Mediated Radiosensitization of ¹⁷⁷Lu-DOTATATE in Neuroblastoma Tumor Spheroids

A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma

Johansson, Patrik; Krona, Cecilia; Kundu, Soumi; Doroszko, Milena et al.

Ingår i Cell Reports, 2020

• DOI för A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma
• Ladda ner fulltext (pdf) av A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma

The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach

Spiegelberg, Diana; Abramenkovs, Andris; Mortensen, Anja; Lundsten, Sara et al.

Ingår i Scientific Reports, 2020

• DOI för The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach
• Ladda ner fulltext (pdf) av The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach

The radiosensitizer Onalespib increases complete remission in Lu-177-DOTATATE-treated mice bearing neuroendocrine tumor xenografts

Lundsten, Sara; Spiegelberg, Diana; Raval, Nakul; Nestor, Marika

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 980-990, 2020

• DOI för The radiosensitizer Onalespib increases complete remission in Lu-177-DOTATATE-treated mice bearing neuroendocrine tumor xenografts
• Ladda ner fulltext (pdf) av The radiosensitizer Onalespib increases complete remission in Lu-177-DOTATATE-treated mice bearing neuroendocrine tumor xenografts

Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized Lipodisks

Lundsten, Sara; Hernandez, Victor Agmo; Gedda, Lars; Sarén, Tina et al.

Ingår i Nanomaterials, 2020

• DOI för Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized Lipodisks
• Ladda ner fulltext (pdf) av Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized Lipodisks

The HSP90 inhibitor onalespib potentiates Lu-177-DOTATATE therapy in neuroendocrine tumor cells

Lundsten, Sara; Spiegelberg, Diana; Stenerlöw, Bo; Nestor, Marika

Ingår i International Journal of Oncology, s. 1287-1295, 2019

• DOI för The HSP90 inhibitor onalespib potentiates Lu-177-DOTATATE therapy in neuroendocrine tumor cells
• Ladda ner fulltext (pdf) av The HSP90 inhibitor onalespib potentiates Lu-177-DOTATATE therapy in neuroendocrine tumor cells

First in vivo study of the MDM2/MDMX-p53 antagonist PM2 as potentiator of external radiotherapy in wt p53 cancer

Spiegelberg, Diana; Mortensen, Anja C.; Lundsten, Sara; Brown, C. J. et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2018

• DOI för First in vivo study of the MDM2/MDMX-p53 antagonist PM2 as potentiator of external radiotherapy in wt p53 cancer

Potentiating Lu-177-DOTATATE Therapy By HSP90 Inhibition - First In Vivo Study

Lundsten, Sara; Spiegelberg, Diana; Raval, Nakul; Stenerlöw, Bo et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2018

The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors

Spiegelberg, Diana; Mortensen, Anja; Lundsten, Sara; Brown, Christopher J. et al.

Ingår i Cancer Research, s. 5084-5093, 2018

• DOI för The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors

Radioiodination Of Small Stapled Peptides For p53 Therapy

Lundsten, Sara; Spiegelberg, Diana; Agmo Hernández, Víctor; Brown, C. et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2017

The HSP90-inhibitor Onalespib Potentiates Lu-177-Dotatate Treatment of Neuroendocrine Tumors

Lundsten, Sara; Mortensen, Anja; Makiniemi, A.; Spiegelberg, Diana et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2017

In Vivo Assessment of p53 Therapy as a Way of Enhancing Therapeutic Effects of Radiation

Mortensen, Anja C.; Spiegelberg, Diana; Lundsten, Sara; Brown, C. et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2017

In Vitro and In Vivo Growth Inhibitory and Radiosensitizing Effects of the Anti-HSP90 agent Onalespib

Spiegelberg, Diana; Lundsten, Sara; Mortensen, Anja C.; Abramenkovs, Andris et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2017

Searching for Synergy: Radiosensitization of ¹⁷⁷Lu-DOTATATE

Lundsten, Sara

2022

• Ladda ner fulltext (pdf) av Searching for Synergy: Radiosensitization of ¹⁷⁷Lu-DOTATATE